F25 - Advancing Detection & Treatment: Heart Failure with Preserved Ejection Fraction & Diabetes

Friday, August 8, 2025

3:30 PM – 4:15 PM MT

CE/CME Hours: .75 CE

Pharmacology Hours: .25 CE

Primary Presenter(s)

Kevin Malloy, PharmD, BCPS, BC-ADM, CDCES (he/him/his)

Endocrinology Clinical Pharmacy Specialist
Cleveland Clinic
Lakewood, Ohio

Disclosure(s): No financial relationships to disclose

Co-Presenter(s)

JF

Jullianne Fallon, PharmD, BCCP

Cardiology Clinical Pharmacy Specialist
Cleveland Clinic
University Heights, Ohio

Disclosure(s): No financial relationships to disclose
EM

Emily McElhaney, PharmD, BCCP

Cardiology Clinical Pharmacy Specialist
Cleveland Clinic
Cleveland, Ohio

Disclosure(s): No financial relationships to disclose

Heart failure (HF) is a common complication of diabetes, affecting over 20% of patients. While the overall incidence of HF in the US has been stable, HF with preserved ejection fraction (HFpEF) is rising, in part due to the metabolic disease epidemic. Despite the prevalence of HFpEF, effective therapies for reducing morbidity and mortality have only recently been discovered. With these advancements, it is crucial to screen patients for early diagnosis and the need for therapy for HFpEF. This session will discuss how to recognize, screen, educate, and treat patients with comorbid diabetes and HFpEF. Attendees will learn the latest strategies and tools to improve patient outcomes.

Disclosure(s):

Kevin Malloy, PharmD, BCPS, BC-ADM, CDCES: No financial relationships to disclose

Jullianne Fallon, PharmD, BCCP: No financial relationships to disclose

Emily McElhaney, PharmD, BCCP: No financial relationships to disclose